Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Janone Inc (JAN)

Janone Inc (JAN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Janone Inc 325 E. Warm Springs Road Las Vegas NV 89119 USA

www.janone.com P: 702-997-5968

Description:

JanOne is focused on developing treatments for diseases that cause severe pain. By alleviating pain at the source, JanOne aims to reduce the need for opioid prescriptions to treat disease associated pain that can lead to opioid abuse. The company is also exploring solutions for non-addictive pain medications. Its lead candidate JAN101 is for treating peripheral artery disease (PAD), a condition that affects over 8.5 million Americans. JAN101 demonstrated positive results in a Phase 2a clinical trial, and Phase 2b trials are expected to begin in early 2021. JanOne is dedicated to funding resources toward innovation, technology, and education for PAD, associated vascular conditions and neuropathic pain. JanOne continues to operate its legacy businesses under their current brand names, which are undergoing review to determine appropriate strategic alternatives.

Key Statistics

Overview:

Market Capitalization, $K 20,017
Enterprise Value, $K 35,227
Shares Outstanding, K 8,976
Annual Sales, $ 0 K
Annual Net Income, $ -7,810 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -2,140 K
EBIT, $ -5,450 K
EBITDA, $ -4,000 K
60-Month Beta 2.16
% of Insider Shareholders 3.00%
% of Institutional Shareholders 6.27%
Float, K 8,707
% Float 97.00%
Short Volume Ratio 0.45

Growth:

1-Year Return 126.40%
3-Year Return -68.23%
5-Year Return -44.25%
5-Year Revenue Growth -100.00%
5-Year Earnings Growth 86.67%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.34 on 05/03/24
Next Earnings Date 08/20/24
Earnings Per Share ttm -0.38
EPS Growth vs. Prev Year -61.90%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-5 on 04/22/19

JAN Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -359.71%
Return-on-Assets % -70.26%
Profit Margin % 0.00%
Debt/Equity 0.30
Price/Sales N/A
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share 0.89
Interest Coverage -8.79
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar